David Hallal bags another whopper round, looking to recruit more cell and gene therapy upstarts to ElevateBio BaseCamp
Less than a year after attracting a launch round of $150 million, ex-Alexion chief David Hallal isn’t breaking stride — yet — for a pandemic. His startup cell and gene therapy player ElevateBio in Waltham, MA has attracted another whopper round, with ambitious plans to build up its portfolio of upstarts.
The latest round includes a bevy of new investors: The Invus Group, Surveyor Capital, EDBI, and Vertex Ventures — backed by Temasek. They’re signing up alongside existing investors, including F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, and Samsara BioCapital.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.